No Data
Buy Rating Affirmed: Achieve Life Sciences' Promising Path to Cytisinicline NDA and Strong Financial Outlook
Buy Rating Affirmed for Achieve Life Sciences Amid Positive Drug Development Progress and Strong Financial Position
Achieve Life Sciences Is Maintained at Outperform by Oppenheimer
Achieve Life Sciences Is Maintained at Outperform by Oppenheimer
Oppenheimer: Maintain the Achieve Life Sciences (ACHV.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $18.00 to $11.00.
Oppenheimer: Maintain the Achieve Life Sciences (ACHV.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $18.00 to $11.00.
Oppenheimer Maintains Outperform on Achieve Life Sciences, Lowers Price Target to $11
Oppenheimer analyst Francois Brisebois maintains Achieve Life Sciences (NASDAQ:ACHV) with a Outperform and lowers the price target from $18 to $11.
Achieve Life Sciences Inc (ACHV) Reports Q1 2024 Financial Results